Admescope launches new services

Company looks to serve growing biologics market
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
OULU, Finland—Late last year, Admescope Ltd., a provider of ADME-Tox contract research services, announced the launch of services for a new category: Biologics.
 
The number of drug development projects with biological drugs has been continuously increasing over the past decade, and therefore the expansion to serve this growing market was considered “a logical continuation” for Admescope’s service development, after having previously built a strong and comprehensive service portfolio for the research of small molecules and peptides.
 
At launch, Admescope’s service offering for biological drugs consists of protein molecular weight and structural characterization, targeted protein quantification, peptide mapping and detection of post-translational modifications, and protein pharmacokinetics.
 
Dr. Ari Tolonen, CEO of Admescope, said “We are thrilled to add another notable step on our growth path this year, following the successful acquisition of MetaSafe AB in June. With the group of experienced protein scientists that we have recruited for our Biologics’ team, we are able to serve the growing segment of biological drug development with the same high quality and expertise that our customers are used to with our services for small molecules and peptides.”

Related Topics

Published In

Volume 15 - Issue 1 | January 2019

January 2019

January 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue